Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Appointed CFO
GILEAD SCIENCES, INC. (GILD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Investor presentation
Docs: "Byoung Chul Cho, Yonsei Cancer Center, Republic of Korea 2 DRAFT Introduction • PD-1 inhibitor-based regimens have been established as the standard-of-care 1L treatment for mNSCLC,1,2 and novel combination therapies are needed to further improve outcomes • Sacituzumab govitecan is a Trop-2–directed ADC approved in the United States for the treatment of 2L+ mTNBC and pretreated HR+/HER2– mBC, and received accelerated approval for 2L mUC3 • Sacituzumab govitecan has previously demonstrated clinical activity and manageable safety in heavily pretreated patients with mNSCLC4 • EVOKE-02 is an ongoing, multicohort phase 2 study of sacituzumab govitecan + pembrolizumab ± platinum agent in patients with untreated 1L mNSCLC • Here, we report preliminary result..."
08/03/2023 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS"
05/05/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
02/02/2023 8-K Quarterly results
10/27/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure  Interactive Data
08/02/2022 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS"
07/28/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/28/2022 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS"
03/07/2022 8-K Quarterly results
02/01/2022 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS"
02/01/2022 8-K Results of Operations and Financial Condition  Interactive Data
01/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/28/2021 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS"
07/29/2021 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS"
05/14/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
01/06/2021 8-K/A Quarterly results
12/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "JEFFREY A. BLUESTONE JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS"
10/28/2020 8-K Quarterly results
Docs: "GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS"
10/23/2020 8-K Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits  Interact...
Docs: "GILEAD SCIENCES COMPLETES ACQUISITION OF IMMUNOMEDICS, INC."
10/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ANTHONY WELTERS JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS"
09/30/2020 8-K Quarterly results
09/29/2020 8-K Quarterly results
09/14/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
06/16/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "JAVIER RODRIGUEZ JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS"
05/08/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy